Ohio Pharmacy Board industry registration $9 mil. annual charge is unconstitutional -- NPA court brief.
Executive Summary
OHIO PHARMACY BOARD INDUSTRY REGISTRATION WOULD COST $9 MIL. annually, NPA asserts in an amicus curiae brief filed Jan. 18 in Ferndale Laboratories Inc. v. Cavendish et al. The National Pharmaceutical Alliance submitted the friend of the court brief with the Cincinnati, Ohio circuit court in support of an appeals court decision to overturn the Ohio State Board of Pharmacy requirement that out-of-state pharmaceutical manufacturers, distributors and wholesalers must be licensed to ship goods into Ohio. NPA states its support of the court's judgment that the Ohio Board "unconstitutionally burdens interstate commerce" by requiring licensing of out-of-state pharmaceutical manufacturers, distributors and wholesalers shipping goods into Ohio.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth